← Back to Treatments
🏅 FDA Orphan Designation

Filsuvez

BIRCH TRITERPENES

Manufacturer: Chiesi USA, Inc.

Indicated for:
Junctional epidermolysis bullosaOrphanDystrophic epidermolysis bullosa

FDA-Approved Indications (2)

Treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older

indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older

Population: adult and pediatric patients 6 months of age and older

Indications & Usage

1 INDICATIONS AND USAGE FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older. ( 1 )

💙 Support Programs

View all →
Filsuvez
Chiesi USA, Inc.
Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.